June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Short-term vision gains at 12 weeks correlate with long-term vision gains at 2 years – Results from the BEVORDEX randomized clinical trial of bevacizumab versus dexamethasone implants for diabetic macular edema
Author Affiliations & Notes
  • Hemal Mehta
    Ophthalmology, Royal Free London NHS Foundation Trust, London, United Kingdom
    Macular Research Group, Save Sight Institute, University of Sydney, Sydney, New South Wales, Australia
  • Samantha Fraser-Bell
    Macular Research Group, Save Sight Institute, University of Sydney, Sydney, New South Wales, Australia
  • Vuong Nguyen
    Macular Research Group, Save Sight Institute, University of Sydney, Sydney, New South Wales, Australia
  • Mark C Gillies
    Macular Research Group, Save Sight Institute, University of Sydney, Sydney, New South Wales, Australia
  • Footnotes
    Commercial Relationships   Hemal Mehta, Allergan (R), Bayer (R), Novartis (R); Samantha Fraser-Bell, Allergan (R); Vuong Nguyen, None; Mark Gillies, Allergan (C), Bayer (C), Novartis (C)
  • Footnotes
    Support  Australian National Health and Medical Research Council Project Grant 632667, 2009-01024. Supplemented by unrestricted educational grant from Allergan.
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 1895. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Hemal Mehta, Samantha Fraser-Bell, Vuong Nguyen, Mark C Gillies; Short-term vision gains at 12 weeks correlate with long-term vision gains at 2 years – Results from the BEVORDEX randomized clinical trial of bevacizumab versus dexamethasone implants for diabetic macular edema
      . Invest. Ophthalmol. Vis. Sci. 2017;58(8):1895.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To determine whether early vision gains provide prognostic long-term information regarding visual outcomes in the management of diabetic macular edema.

Methods : Post-hoc analysis of 68 study eyes that completed 2 year follow-up of the BEVORDEX multi-center randomised clinical trial set in Australia (ClinicalTrials.Gov identifier: NCT01298076). Eyes were stratified by VA (visual acuity) change in the first 12 weeks in to 3 groups: (a) No gain: < 5 letter gain (includes VA loss), (b) Small gain: 5-9 letter gain, (c) Large gain: ≥ 10 letter gain. To account for correlation between eyes from the same patient, generalised estimated equations (GEEs) were used.

Results : The change in VA in the first 12 weeks was significantly correlated with VA change at 104 weeks (P < 0.001, GEE). This was independent of lens status at baseline (P = 0.726; GEE) or treatment allocation (P = 0.614, GEE). The degree of visual acuity improvement at 12 weeks and 2 years did not correlate with central macular thickness improvement (P = 0.736, GEE). Those study eyes with large VA gain at 12 weeks started with worse baseline VA than the small VA gain group ending up with similar VA at 104 weeks. The no VA gain group had similar baseline VA to the small VA gain group but did not exhibit VA improvement at 12 or 104 weeks.

Conclusions : Short-term visual gain at 12 weeks is strongly correlated with long-term vision improvement. Early improvement in central macular thickness was not predictive of long-term visual outcomes.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×